Needham analyst Serge Belanger initiated coverage of Zogenix with a Buy rating and $58 price target, citing its Fintepla drug returning to the path of a potential regulatory approval by the FDA. The analyst contends that the drug will play a "niche but consequential role" in treating rare pediatric epilepsy disorders given the high levels of efficacy and seizure freedom in treating Dravet Syndrome, or DS, patients. Belanger believes that Fintepla will be approved by the FDA in the first half of next year thanks to its efficacy and manageable safety profile, as well as a "significant unmet need in DS."